75 related articles for article (PubMed ID: 24091113)
1. Management of anaemia and other treatment complications.
Hézode C
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S337-42. PubMed ID: 24091113
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Hézode C
Liver Int; 2012 Feb; 32 Suppl 1():32-8. PubMed ID: 22212569
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
4. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
5. How to optimize HCV therapy in genotype 1 patients: management of side-effects.
Chopra A; Klein PL; Drinnan T; Lee SS
Liver Int; 2013 Feb; 33 Suppl 1():30-4. PubMed ID: 23286843
[TBL] [Abstract][Full Text] [Related]
6. Management of side-effects.
Rosa I
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S69-74. PubMed ID: 22248698
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
8. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Cacoub P; Bourlière M; Lübbe J; Dupin N; Buggisch P; Dusheiko G; Hézode C; Picard O; Pujol R; Segaert S; Thio B; Roujeau JC
J Hepatol; 2012 Feb; 56(2):455-63. PubMed ID: 21884670
[TBL] [Abstract][Full Text] [Related]
9. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
10. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
11. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
Lens S; Calleja JL; Campillo A; Carrión JA; Broquetas T; Perello C; de la Revilla J; Mariño Z; Londoño MC; Sánchez-Tapias JM; Urbano-Ispizua Á; Forns X
World J Gastroenterol; 2015 May; 21(17):5421-6. PubMed ID: 25954117
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.
Biesbroeck LK; Scott JD; Taraska C; Moore E; Falsey RR; Shinohara MM
Am J Clin Dermatol; 2013 Dec; 14(6):497-502. PubMed ID: 23775427
[TBL] [Abstract][Full Text] [Related]
13. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
14. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
[TBL] [Abstract][Full Text] [Related]
15. [New triple therapy in chronic hepatitis C. Increased patient chances].
Stiefelhagen P
MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
[No Abstract] [Full Text] [Related]
16. [Management of side effects induced by antiviral therapy for chronic hepatitis infection].
Smolić M; Smolić R; Vcev A
Acta Med Croatica; 2013 Oct; 67(4):383-7. PubMed ID: 24984340
[TBL] [Abstract][Full Text] [Related]
17. Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Kozielewicz D; Halota W; Dybowska D
Przegl Epidemiol; 2013; 67(4):623-8,713-6. PubMed ID: 24741907
[TBL] [Abstract][Full Text] [Related]
18. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
Mauss S; Hueppe D; Alshuth U
Hepatology; 2014 Jan; 59(1):46-8. PubMed ID: 23813604
[TBL] [Abstract][Full Text] [Related]
19. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
Dumortier J; Guillaud O; Gagnieu MC; Janbon B; Juillard L; Morelon E; Leroy V
J Clin Virol; 2013 Feb; 56(2):146-9. PubMed ID: 23149155
[TBL] [Abstract][Full Text] [Related]
20. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
Borroni G; Cazzaniga M; Andreoletti M; Ceriani R; Guerzoni P; Omazzi B; Pich MG; Prada A; Spinzi G; Terreni N; Salerno F
J Viral Hepat; 2013 Apr; 20(4):e90-5. PubMed ID: 23490395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
